Gene therapy for corneal disease holds promise but still has limitations, according to one speaker at the virtual EuCornea congress.
“In ophthalmology, most clinical trials are related to disorders of the retina, while for cornea, they are still very few,” Victor Abad Morales, PhD, said.
He said that requirements for corneal gene therapy are stringent. First, vision must be significantly impaired or likely to be so in the near future, and no better equivalent effective treatment must be available. Second, the genetic defect involved must be clearly identified, and third, the
Uncategorized